Bristol Myers Squibb
Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial
ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent
Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal
Differences and potential advantages of aficamten compared to BMS’s Camzyos
The recent analysis from Cytokinetics has highlighted several key differences and potential advantages of aficamten compared to Bristol Myers Squibb’s Camzyos, both of which are cardiac myosin inhibitors used in the treatment of obstructive hypertrophic cardiomyopathy (HCM). Key Differences Pharmacodynamic Profile: Aficamten, being a next-generation myosin inhibitor, has a different pharmacodynamic profile compared to mavacamten […]
BMS Collaborates to Revolutionize Immunotherapy: The Repertoire Vaccine Partnership
BMS, Bristol-Myers Squibb, Repertoire, immunotherapy, vaccine, immune system reset, partnership, cancer treatment, personalized medicine.
Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development
Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.